Safety and tolerability of mRNA COVID-19 vaccines in people with antiphospholipid antibodies

Lancet Rheumatol. 2021 Dec;3(12):e832. doi: 10.1016/S2665-9913(21)00320-9. Epub 2021 Oct 20.

Savino Sciascia^{1

2}, Piera Costanzo³, Massimo Radin^{1

2}, Karen Schreiber^{4

5

6}, Massimo Pini⁷, Antonella Vaccarino⁷, Irene Cecchi^{1

2}, Simone Baldovino^{1

2}, Dario Roccatello^{1

2}

¹ CMID-Nephrology and Dialysis Unit (ERK-net member), Research Center of Immunopathology, Coordinating Center of the Network for Rare Diseases of Piedmont and Aosta Valley, San Giovanni Bosco Hub Hospital, 10154 Turin, Italy.
² Department of Clinical and Biological Sciences, University of Turin, Turin, Italy.
³ Cardiology Unit, Coordinating Center of the Network for Rare Diseases of Piedmont and Aosta Valley, San Giovanni Bosco Hub Hospital, 10154 Turin, Italy.
⁴ Danish Hospital for Rheumatic Diseases, Sønderborg, Denmark.
⁵ Department of Regional Health Research, University of Southern Denmark, Odense, Denmark.
⁶ Centre for Haemostasis and Thrombosis, Guy's and St Thomas' NHS Foundation Trust, London, UK.
⁷ Hematology Unit, Coordinating Center of the Network for Rare Diseases of Piedmont and Aosta Valley, San Giovanni Bosco Hub Hospital, 10154 Turin, Italy.

No abstract available